New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
08:17 EDTMRTXMirati Therapeutics price target raised to $27 from $20 at Brean Capital
Brean Capital raised its price target on Mirati Therapeutics as the company continues to move its pipeline forward, positive trials updates, and expectations for upfront payments and royalties from potential partnerships. Shares are Buy rated.
News For MRTX From The Last 14 Days
Check below for free stories on MRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 11, 2014
08:04 EDTMRTXMirati Therapeutics receives orphan designation from FDA for mocetinostat
Subscribe for More Information
August 8, 2014
10:07 EDTMRTXMirati Therapeutics unit gets orphan drug designaion for mocetinostat
Subscribe for More Information
08:06 EDTMRTXMirati Therapeutics says Phase 1 study of MGCD265 ongoing
Subscribe for More Information
08:05 EDTMRTXMirati Therapeutics reports Q2 EPS (82c), consensus (69c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use